A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Proof of concept
- Sponsors Incyte Corporation
- 17 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 25 Jun 2017 Results of 21-marker FACS analysis, presented at the 22nd Congress of the European Haematology Association.
- 09 Aug 2016 According to an Incyte Corporation media release, initial data from this trial is expected before the end of 2016.